Zydus Cadila’s Nortriptyline Hydrochloride capsules receive approval from the USFDA
Zydus Cadila will soon launch the antidepressant drug Nortriptyline Hydrochloride into the market. This drug received the final approval from the USFDA on 25 February 2021.
The health regulator permitted the sale of the 10 mg, 25 mg, 50 mg, and 75 mg strength of the capsule.
Nortriptyline Hydrochloride capsules are indicated for mental and mood problems like depression. It helps to improve mood and feelings of well–being and also relieves anxiety and tension. Apart from this, it also increases one’s energy level. 1
Cadila Healthcare will manufacture this newly approved drug will at the group’s manufacturing facility. This facility is located at SEZ in Ahmedabad.
Currently, this group possesses over 313 approvals and has filed more than 400 ANDA since the filing process in 2003 – 2004.
Depression is one of the leading types of mental illness where there is a constant feeling of sadness that prevails for weeks or months. Sadness for a few days cannot be concluded as depression. Depression not only makes a person feel low, but it also affects our ability to do our activities. The person becomes so low mentally that they avoid indulging in any activity. Read more: Depression: a constant feeling of sadness
- The most widely used drugs in treating depressive disorders are Selective serotonin reuptake inhibitors (SSRIs) and Tricyclic and related antidepressants. A patient may take 4-6 weeks to respond to antidepressant therapy. It is advisable to review progress every 1-2 weeks at the start of treatment. The patient should continue treatment for at least four weeks before considering changing to another antidepressant due to lack of efficacy.
- Zydus Cadila: Popular Brands, Composition, and Pack Details
- 1. The United States Food and Drug Administration
- 2. Special Economic Zone
- 3. Abbreviated New Drug Application